This content is in French.
How are new therapies transforming the management of metastatic castration-resistant prostate cancer?
18 novembre 2025
By Lila Rouland | Published on November 18, 2025 | 3 min readMetastatic castration-resistant prostate cancer (mCRPC) remains an incurable disease despite a decade of significant therapeutic progress. The clinical objective is no longer limited to survival, but now also includes quality of life (QoL) and symptom control. The biological heterogeneity of mCRPC, marked by increasing genomic complexity
By Lila Rouland | Published on November 18, 2025 | 3 min read
Metastatic castration-resistant prostate cancer (mCRPC) remains an incurable disease despite a decade of significant therapeutic progress. The clinical objective is no longer limited to survival, but now also includes quality of life (QoL) and symptom control. The biological heterogeneity of mCRPC, marked by increasing genomic complexity, calls for a personalized approach based on biomarkers to guide therapeutic decisions. This review summarizes current treatments, targeted innovations, and upcoming clinical challenges.
Metastatic castration-resistant prostate cancer (mCRPC) remains an incurable disease despite a decade of significant therapeutic progress. The clinical objective is no longer limited to survival, but now also includes quality of life (QoL) and symptom control. The biological heterogeneity of mCRPC, marked by increasing genomic complexity, calls for a personalized approach based on biomarkers to guide therapeutic decisions. This review summarizes current treatments, targeted innovations, and upcoming clinical challenges.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Metastatic Castration Resistant Prostate Cancer: Advances in Treatment and Symptom Management. Kulasegaran T, Oliveira N Current Treatment Options in Oncology. 2024;25:914–931.
View the source
